logo-loader
viewDyadic International Inc

Dyadic International says C1 antigen shows strong performance in protecting animals from devastating virus

The company updated investors on a busy fourth quarter that saw new partnerships and positive scientific results

Dyadic International Inc -
Initial results from ongoing studies look promising

Dyadic International Inc (NASDAQ:DYAI) told investors Monday that it is pleased with the preliminary results from its ZAPI animal study.

The firm said that initial results from the study indicated that Dyadic’s C1 antigen showed strong performance in protecting cattle and mice from the devastating Schmallenberg virus, which causes congenital malformations in certain animals.

The positive news means ZAPI is expanding the scope of Dyadic’s involvement in the program, the firm said in a release.

READ: Noble Capital keeps Outperform rating on Dyadic and ratchets up price target to $11

Dyadic expects to get more funding from the ZAPI consortium to support the production of two additional targets. Final results from the study should be published in the second quarter of 2020, according to Dyadic CEO Mark Emalfarb.

The company is working on two additional proteins for the animal health market, Emalfarb told shareholders. It already has ongoing collaborations with two of the top four animal health companies.

Emalfarb shared the news as part of a wider business update that highlighted scientific results from a busy fourth quarter for the company.

Dyadic is expanding its research relationship with the microbial fermentation group of a major pharmaceutical company to evaluate C1 for their own internal use, the company said Monday. The nonexclusive license allows Dyadic’s collaborator to perform certain experiments and manipulations to the C1 cell lines to create potential licensed products, as well as other internal noncommercial purposes.

Emalfarb called the strengthened relationship an “exciting endorsement” of the potential of its C1 technology.

“Our ongoing fully funded research collaboration with this collaborator helped us to obtain a research license with another part of the global organization where we will tech transfer our C1 technology to their in-house lab for their scientists to further evaluate it, possibly improving upon it, with the objective of broadening and accelerating the adoption and use of C1 globally,” Emalfarb said.

The expanding business portfolio further highlights the significant runway for value creation at Dyadic, he added.

The collaborator will invest its own resources to evaluate C1 technology for their customers globally.

READ: Dyadic achieves human-like glycan structures from engineered C1 cell line

In a separate collaboration between Dyadic and the Israeli Institute of Biological Research (IIBR), a proprietary IIBR Fc-fusion enzyme has been expressed using C1 technology.

The Acetyl Choline Esterase enzyme has previously been shown to provide certain countermeasures against nerve agents such as sarin and VX gas which are toxic and rapidly acting chemical warfare agents, according to Dyadic. The recombinant IIBR Fc-fusion enzyme provides longer protection than the common Acetyl Choline Esterase, the firm said.

"This collaboration with IIBR demonstrates a new class of proteins that can be expressed from C1 to produce larger amounts of lower cost countermeasures for chemical and biological threats globally,” Emalfarb said in a statement.

Additional highlights come from the firm’s glycoengineering program that demonstrated the potential applicability of the C1 technology for developing and manufacturing types of biosimilar, biobetters and new biomolecules.

Emalfarb said that Dyadic should be able to develop and manufacture biopharmaceuticals for certain diseases, including cancer and arthritis, in large volumes at lower cost.

Also in 4Q, Dyadic partnered with a top ten pharmaceutical company and filed two additional patent applications.

Dyadic will be attending the JP Morgan conference in San Francisco on January 12 and 13 to discuss the company’s progress.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Dyadic International Inc

Price: 5.25 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $142.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Dyadic CEO remarks on steps the federal gov't can take to speed along drug...

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb sat down with Proactive at the Biotech Showcase 2020 in San Francisco. Emalfarb talks about how there's a lot of things the government can do to speed the development of new biologics to the market. Namely, by offering a simliar orphan...

on 01/16/2020

3 min read